Risk of combining clopidogrel with proton pump inhibitors – significance and possible solutions

Česká verzia

Authors: J. Bultas
Authors place of work: Ústav farmakologie 3. LF UK Praha
Published in the journal: Gastroent Hepatol 2010; 64(4): 25-31
Category: IBD: Aktuální přehled

Summary

Proton pump inhibitors (PPIs) and clopidogrel are very frequently used drugs; unfortunately, their concurrent administration may result in failure of the antiplatelet effect and in an acute atherothrombotic event. The basis of this drug interaction is an insufficient bioactivation of the prodrug – clopidogrel – by inhibition of the key isoenzyme CYP2C19 induced by certain PPIs.

Studies monitoring platelet functions, in particular aggregability, demonstrate distinctive long-term reduction of the clopidogrel effect on the inhibition of both activation and aggregation of thrombocytes in co-medication with omeprazole and lanzoprazole; less if pantoprazole or esomeprazole are administered. Within the laboratory testing of primary haemostasis and the effect of inhibition of bioactivation of clopidogrel by PPIs, results are consistent. However, the situation is different in studies monitoring prognostic indicators. Here, the results of observation studies, often analyzing a high risk population, demonstrate a distinctive increase in coronary events; meta-analysis of almost 60 thousand patients demonstrates an increase of more than 50 %. Analyses of randomized studies, unfortunately of the post hoc type, identify a significantly lower risk, the occurrence of acute coronary events increased with co-medication insignificantly, by just 15 %. Nevertheless, comprehensive analyses of all studies, featuring more than 90 thousand patients, identify an increased risk of coronary events of 43 % and of all serious cardiovascular events of 25 %. When analysing this schism, it is shown that randomised studies were performed on a significantly lower risk population (with an annual event risk below 10 %). When monitoring the effect of co-medication of clopidogrel with PPIs on low- and high-risk populations of cardiac patients, it is shown that the increased risk of occurrence of a serious cardiovascular event (death, myocardial infarction or ictus) occurs only in patients with an annual event risk over 10 %.

In practice, such drug interaction can be avoided by selecting a therapy other than PPI administration, or perhaps by administering pantoprazole, esomeprazole or optimally rabeprazole, by selecting another platelet ADP receptor inhibitor, in particular prasugrel, or by increasing the dose of clopidogrel.

Key words:
clopidogrel – proton pump inhibitors – drug interactions – CYP2C19

Zdroje

1.Cuisset T, Frere C, Quilici J et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54(13):1149–1153.

2.Siller-Matula JM, Spiel AO, Lang IM et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009; 157(1): 148.e1–5.

3.Sibbing D, Morath T, Stegherr J et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101(4): 714–719.

4.Liu TJ, Jackevicius CA et al. Drug interaction between clopidogrel and proton pump inhibitors. Pharmacotherapy 2010; 30(3): 275–289.

5.http://www.emea.europa.eu – EMEA public statement on possible interaction between clopidogrel and proton pump inhibitors.

6.Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors – focus on rabeprazole. Aliment Pharmacol Ther 2004; 20 Suppl 6: 11–19.

7.Hulot JS, Collet JP, Silvain J et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56(2): 134–143.

8.Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360(4): 363–375.

9.Cuisset T, Frere C, Quilici J et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol 2009; 54(13): 1149–1153.

10.Wiviott SD and PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116(25): 2923-32.

11.Aubert RE, Epstein RS, Teagarden JR et al. Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study (abstr). Circulation 2008; 118: S815.

12.Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 30: 937–944.

13.Kwok CS, Loke YK. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010; 31(8): 810–823.

14.O'Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989–997.

15.Hulot JS, Collet JP, Silvain J et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56(2): 134–143.